Handan ANKARALI, Süreyya EKEM, H. Tuğrul ATASOY, Nida Fatma TAŞCILAR, Esra ACIMAN DEMİREL, Banu BARUT ÖZEN

Tipik ve Atipik Antipsikotik İlaç Kullanımına Bağlı EEG Anormallikleri

Amaç: Tipik antipsikotikler ve klozapin EEG anormalliklerine ve epileptik nöbetlere neden olabilir. Yeni kuşak antipsikotiklerin EEG üzerindeki etkileri çok fazla bilinmemektedir. Yapılan bu çalışmada klozapin, ketiapin, risperidon ve olanzapin gibi atipik antipsikotikler, amisülpirid, aripiprazol, paliperidon gibi yeni diğer atipik antipsikotikler ve klorpromazin, haloperidol, zuklopentiksol, pimozid gibi tipik antipsikotiklerin EEG anormallikleri üzerine etkileri araştırılmıştır. Gereç ve Yöntemler: Şizofreni veya şizoaffektif bozukluk tanılı 102 hasta prospektif olarak değerlendirilerek EEG'leri çekildi. Bunların 82'si atipik [klozapin (n:16), risperidon (n:20), ketiapin (n:10), olanzapin (n:14), diğer yeni atipik antipsikotikler (n:10)] ve tipik [haloperidol (n:5), klorpromazin (n:2), zuklopentiksol (n:3), pimozid (n:2)] antipsikotik kullanıyordu, 20'si ise ilaç kullanmıyordu. Bu üç alt grup; cinsiyet ve yaş uyumlu sağlıklı kontrol grubunun (n=29) EEG'leri ile karşılaştırıldı. Bulgular: Gruplar arasında demografik özellikler bakımından istatiksel olarak anlamlı fark saptanmadı. Hem ilaç kullanmayan hastaların hem de sağlıklı kontrollerin EEG'leri normaldi. Klozapin kullanan hastaların % 31,3'ünde (p0,05) epileptik aktivite gözlendi. Epileptik aktivite dışındaki EEG anormallikleri tipik antipsikotik kullananların %58,3'ünde (p

EEG Abnormalities Associated with the Use of Typical and Atypical Antipsychotics

Aim: Typical antipsychotics and clozapine could cause EEG abnormalities and risk of epileptic seizures. Little is known about the effects of newer antipsychotics on EEG. The present study therefore examined the risk of EEG abnormalities associated with the use of atypical antipsychotics [clozapine, quetiapine, risperidone, olanzapine and new atypical antipsychotics (amisulpride, aripiprazole, paliperidone)] and of the typical antipsychotics (chlorpromazine, haloperidol, zuclopenthixol, pimozide). Materials and Methods: EEG patterns were prospectively investigated in 102 patients with schizophrenia or schizoaffective disorders. While 82 out of the 102 patients were under atypical [clozapine (n=16), risperidone (n=20), quetiapine (n=10), olanzapine (n=14), and new atypical antipsychotics (n=10)] and typical [haloperidol (n=5), chlorpromazine (n=2), zuclopenthixol (n=3), pimozide (n=2)] antipsychotic treatment, 20 of them were not under any treatment. These three groups were compared with a sex- and aged- matched control group of healthy volunteers (n=29). Results: No statistically significant difference regarding demographic characteristics was found between the groups. Both the patients who were not on any medication and the healthy volunteers had normal EEG's. Epileptic activity was observed in 31.3% of the patients under clozapine treatment (p0.05). EEG abnormalities other than epileptic activity were observed in 58.3% of the patients under typical antipsychotics (p

PDF

___

Centorrino F, Price BH, Tuttle M, Bahk WM, Hennen J, Albert MJ, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychi- atry. 2002;159(1):109-15.
Roubicek J, Major I. EEG profile and behavioral changes after a single dose of clozapine in normals and schizoph- renics. Biol Psychiatry. 1977;12(5):613-33.
Moore NC, Tucker KA, Brin FB, Merai P, Shillcut SD, Coburn KL. Positive symptoms of schizophrenia: Res- ponse to haloperidol and remoxipride is associated with increased alpha EEG activity. Hum Psychopharmacol. 1999;12(1):75-80.
Stevens JR, Bigelow L, Denney D, Lipkin J, Livermore AH, Rauscher F, et al. Telemetered EEG-EOG during psychotic behaviors of schizophrenia. Arch Gen Psychi- atry. 1979;36(3):251-62.
Bridgers SL. Epileptiform abnormalities discovered on electroencephalographic screening of psychiatric inpati- ents. Arch Neurol. 1987;44(3):312-6.
Silvestri RC, Bromfield EB, Khoshbin S. Clozapi- ne-induced seizures and EEG abnormalities in am- bulatory psychiatric patients. Ann Pharmacother. 1998;32(11):1147-51.
Devinsky O, Honigfeld G, Patin J. Clozapine-related sei- zures. Neurology 1991;41(3):369-71.
Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hard- man JG, Limbird LE, Gilman AG (ed.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10. ed. New York: McGraw-Hill; 2001:447-83.
Amerikan Psikiyatri Birliği. Psikiyatride Hastalıkla- rın Tanımlanması ve Sınıflandırılması El Kitabı, 4. ed. (DSM-IV TR), (çev. Ertuğrul Köroğlu). Ankara: Hekim- ler Yayın Birliği; 2001:137-42.
American Electroencephalographic Society. Guideline seven: a proposal for standard montages to be used in clinical EEG. J Clin neurophsiol. 1994;11(1):30-6.
Small JG. Psychiatric disorders and EEG. In: Nieder- meyer E, DaSilva FL (ed.), Electroencephalography: Basic Principles, Clinical Applications, and Related Fi- elds, 5. ed. Baltimore: Lippincott Williams & Wilkins; 1999:639-61.
Aminoff MJ. Electroencephalography: general principles and clinical applications. In: Aminoff MJ (ed.), Electro- diagnosis in Clinical Neurology, 3. ed. New York: Churc- hill-Livingstone; 1992:41-91.
Saletu B, Anderer P, Kinsperger K, Grünberger J. To- pographic brain mapping of EEG in neuropsychop- harmacology. Part II: Clinical applications (pharma- co EEG imaging). Methods Find Exp Clin Pharma- col.1987;9(6):385-408.
Westphal KP, Grozinger B, Diekmann V, Scherb W, Re- ess J, Leibing U, et al. Slower theta activity over the midf- rontal cortex in schizophrenic patients. Acta Psychiatr Scand. 1990;81(2):132-8.
Jirsch JD, Urrestarazu E, LeVan P, Olivier A, Dubeau F, Gotman J. High-frequency oscillations during human focal seizures. Brain. 2006;129(6):1593-608.
Staba RJ, Wilson CL, Bragin A, Fried I, Engel J Jr. Qu- antitative analysis of high-frequency oscillations (80-500 Hz) recorded in human epileptic hippocampus and en- torhinal cortex. J Neurophysiol. 2002;88(4):1743-52.
Yağcıoğlu EA. Antipsikotik ilaçların etki mekanizmaları: şizofreni tedavisinde "atipiklik" bir üstünlük mü? Türk Psikiyatri Derg. 2007;18(4):364-74.
Amann BL, Pogarell O, Mergl R, Juckel G, Grunze H, Mulert C, et al. EEG abnormalities associated with an- tipsychotics: a comparison of quetiapine, olanzapine, ha- loperidol and healthy subjects. Hum Psychopharmacol. 2003;18(8):641-6.
Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65(4):500-8.
Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268-74.
Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474-86.
Herz MI, Marder SR. Schizophrenia: Comprehensive Treatment and Management. Philadelphia: Lippincott Williams & Wilkins; 2002:9-21.
Conley RR, Meltzer HY. Adverse events related to olan- zapine. J Clin Psychiatry. 2000;61(Suppl 8):26-9.
Kramer M, Simpson G, Maciulis V, Kushner S, Vijapur- kar U, Lim P, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo- controlled study. J Clin Psychopharmacol. 2007;27(1):6- 14.
Olney JW, Farber NB Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry. 1994;55(Suppl B):43-6.
Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neu- rosci. 1994;6(3):250-6.
Ichikawa J, Dai J, O'Laughlin IA. Atypical, but not typi- cal, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002;26(3):325- 39.
Risby ED, Epstein CM, Jewart RD, Nguyen BV, Morgan WN, Risch SC, et al. Clozapine-induced EEG abnorma- lities and clinical response to clozapine. J Neuropsychi- atry Clin Neurosci. 1995;7(4):466-70.
Freudenreich O, Weiner RD, McEvoy JP. Clozapine-in- duced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry. 1997;42(2):132- 37.
Baldessarini RJ, Frankenburg FR. Clozapine: a novel an- tipsychotic agent. N Engl J Med. 1991;324(11):746-54.
Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptoma- tology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychop- harmacology (Berl) 1995;119(2):231-8.
Chengappa KN, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS, et al. Anticholinergic differen- ces among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol. 2000;20(3):311-6.
Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanza- pine. J Clin Psychiatry. 1997;58(Suppl 10):13-7.
Wyderski RJ, Starrett WG, Abou-Saif A. Fatal status epi- lepticus associated with olanzapine therapy. Ann Phar- macother. 1999;33(7-8):787-9.
Stahll SM. Stahl's Essential Psychopharmacology: Neu- roscientific Basis and Practical Application, 3. ed. New York: Cambridge University Press; 2008:401-50.
Jufe G. Psicofarmacología Práctica. Buenos Aires: Edito- rial Polemos; 2001:129-40.
Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical handbook of psychotropic drugs,13. ed. Toronto: Hogrefe & Huber Publishers; 2003:100-29.
Strange PG. Antipsychotic drugs: importance of dopa- mine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev. 2001;53(1):119-33.